Heron Therapeutics (HRTX) Gains from Investment Securities (2010 - 2026)

Heron Therapeutics has reported Gains from Investment Securities for 17 years, with the latest figure at $219000.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities fell 95.09% year-over-year to $219000.0; the trailing twelve-month figure through Mar 2026 stood at $219000.0 (down 95.09% YoY), and the FY2025 full-year result was $28.7 million, up 10.06% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $219000.0, down from $28.7 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $5.5 billion in Q3 2023, with the low at -$96000.0 in Q1 2022.
• Historically, Gains from Investment Securities has averaged $358.3 million across 5 years, with a median of $9.7 million in 2023.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities sank 164.86% — and 2024, when it jumped 78936.36%.
• Heron Therapeutics' Gains from Investment Securities stood at $20.5 million in 2022, then tumbled by 99.84% to $33000.0 in 2023, then jumped by 78936.36% to $26.1 million in 2024, then climbed by 10.06% to $28.7 million in 2025, then sank by 99.24% to $219000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $219000.0 (Q1 2026), $28.7 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.